Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTHEM: Angiotensin 2 for Hepatorenal Syndrome
NCT04048707Phase 2Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of Angiotensin II in hepatorenal syndrome (HRS), sponsored by University of California, Los Angeles. Planned start Jul 2021; status: withdrawn.
02
Drugs
Angiotensin II
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT04048707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048707.